Results 221 to 230 of about 194,359 (349)

Cognitive and Psychomotor Processing Speed in Medication‐Naïve Individuals With First‐Episode of Psychosis: The Role of Peripheral Inflammatory Markers

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background and Hypothesis Deficits in processing speed (PS) and psychomotor speed (PMS) are core cognitive impairments in schizophrenia spectrum disorders, including first‐episode psychosis (FEP). Neuroinflammation has been proposed as a potential contributor to these deficits.
Ángel Yorca‐Ruiz, Carlos Martínez Asensi, Rebeca Magdaleno Herrero, Alexandre Díaz‐Pons, Víctor Ortiz‐García de la Foz, Luis Manuel Fernández Cacho, Ana Catalán Alcantara, Benedicto Crespo‐Facorro, Rosa Ayesa‐Arriola   +8 more
wiley   +1 more source

Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751). [PDF]

Transl Cancer Res
Wang B, Cao L, Li J, Zhao Y, Li J, Wen Y, Yan P, Guo W, Bai O.   +8 more
europepmc   +1 more source

Granulocyte‐Macrophage Colony‐Stimulating Factor Augments Phagocytosis ofMycobacterium aviumComplex by Human Immunodeficiency Virus Type 1–Infected Monocytes/Macrophages In Vitro and In Vivo [PDF]

, 2000
Katherine Kedzierska, Johnson Mak, Anne Mijch, Ian R. C. Cooke, Melissa Rainbird, Sally Roberts, Geza Paukovics, Damien Jolley, Angel F. López, Suzanne M. Crowe   +9 more
openalex   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor as a support for chemotherapy for gestational trophoblastic neoplasia: a propensity score matching analysis. [PDF]

Front Oncol
Zhao X, Zhao H, Sun L, Yan L, Han H, Li Z.   +5 more
europepmc   +1 more source

Prolonged IL‐33 Exposure Switches the Secreted Mast Cell Cytokine Profile From Pro‐Inflammatory to Pro‐Tolerant

Allergy, EarlyView.
This study investigates the effect of IL‐33 and Hymenoptera venom on mast cell cytokine profiles under venom immunotherapy (VIT)‐like conditions. Our in vitro model of VIT‐like mast cell stimulation demonstrates a modulatory effect of IL‐33 on the secreted mast cell cytokine profile.
Andrea R. Teufelberger, Carolin Költgen, Magda Babina, Peter Wolf   +3 more
wiley   +1 more source

Acute Lung Injury in a Healthy Peripheral Blood Stem Cell Donor Following Granulocyte-colony Stimulating Factor Administration: A Case Report. [PDF]

EJHaem
Desai N, Moya TA, Heffering-Cardwell M, Sanchez FT, Michelis FV, Law AD.   +5 more
europepmc   +1 more source

Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia.

, 1988
TR Ulich, J del Castillo, L Souza
openalex   +1 more source

Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats

, 2005
Jin-Cherng Chen, Yun Chen, Jiann-Ming Wu, Yen‐Hao Su, Kuo‐Feng Tai, Sheng-Hong Tseng   +5 more
openalex   +2 more sources

Antibody to Mol abrogates the increase in neutrophil phagocytosis and degranulation induced by granulocyte‐macrophage colony‐stimulating factor [PDF]

, 1989
Y. Kletter, Ilan Bleiberg, David W. Golde, Ina Fabian   +3 more
openalex   +1 more source